Dupilumab for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What is the safety profile of Dupilumab for eczema?
Dupilumab is generally considered safe for treating eczema, with common side effects including injection site reactions, conjunctivitis (eye inflammation), headache, and nasopharyngitis (cold-like symptoms). Some rare side effects have been reported, such as alopecia areata (hair loss) and cicatricial ectropion (eyelid turning outwards).12345
How is the drug Dupilumab unique for treating eczema?
Dupilumab is unique because it is the first FDA-approved biological therapy for moderate-to-severe eczema that works by blocking the IL-4 receptor, which helps reduce inflammation. Unlike traditional topical treatments, it is administered as an injection and is specifically designed for patients whose eczema is not well-controlled with topical therapies.25678
What data supports the effectiveness of the drug Dupilumab for eczema?
Dupilumab has been shown to improve symptoms of moderate-to-severe eczema, such as skin inflammation, itching, and sleep problems, in adults and adolescents who did not respond well to other treatments. It works by blocking certain proteins in the body that cause inflammation, and its benefits have been maintained for up to a year with continued use.2891011
Who Is on the Research Team?
Jeffrey Cheng, MD, PhD
Principal Investigator
University of California, San Francisco
Raymond Cho, MD, PhD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for adults over 18 with moderate to severe eczema, as shown by an EASI score of 7 or more. It's not open to those who are pregnant, have a known parasitic infection, or suffer from immunodeficiencies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment with the IL4RA inhibitor dupilumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dupilumab
Dupilumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor